According to the data fromthe State Register of Medicines (GRLS), on July 4, the Ministry of Health of the Russian Federation registered Salnavac, a nasal two-component vaccine against coronavirus infection, manufactured by Generium, a Russian pharmaceutical company. The company submitted the application for the registration of Salnavac to the Ministry in April 2022.
The drug is a combined vector vaccine in the form of a nasal spray for the prevention of coronavirus. The vaccine consists of two components. Both of them include a recombinant adenovirus vector based on human adenovirus.
The drug is administered intranasally, with an interval of three weeks between the introduction of components (prime-boost mode).
The vaccine causes activation of systemic humoral and cellular immunity and, as it is confirmed by clinical trials, forms mucosal immune protection against COVID-19 on the surface of the mucous membrane of the respiratory tract.
On April 1, the Ministry of Health of the Russian Federation registered the world’s first nasal vaccine against COVID-19.
The Russian Ministry of Health has also registered a nirmatrelvir-based therapy for COVID-19.
